Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05862272 · ClinicalTrials.gov registry record · Phase 3
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
A Phase 3 study of Endometriosis and Uterine Fibroids, sponsored by Sumitomo Pharma Switzerland.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT05862272: Recruiting Phase 3 study of Endometriosis and Uterine Fibroids, sponsored by Sumitomo Pharma Switzerland.
NCT05862272 is a Phase 3 study of Endometriosis and Uterine Fibroids that is actively recruiting participants, run by Sumitomo Pharma Switzerland. The registered enrollment target is 1,000 participants, above the 243-participant average among 48 other Endometriosis trials with a reported enrollment target (312% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05862272, a Phase 3 study of Endometriosis and Uterine Fibroids, is actively recruiting participants, sponsored by Sumitomo Pharma Switzerland.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Primary Outcome
Assessed by dual-energy X-ray absorptiometry (DXA) scan.
Conditions Studied
Interventions
- DRUG Relugolix Combination Tablet
Study Locations (20)
California
- Burbank - Burbank
- Canoga Park - Canoga Park
- Encinitas - Encinitas
- Inglewood - Inglewood
- Lomita - Lomita
- Long Beach - Long Beach
- Los Angeles - Los Angeles
- Sacramento - Sacramento
- San Fernando - San Fernando
- Stanford - Stanford
- Valley Village - Valley Village
Arizona
- Chandler - Chandler
- Mesa - Mesa
- Peoria - Peoria
- Phoenix - Phoenix
- Tucson - Tucson
Colorado
- Aurora - Aurora
- Greenwood Village - Greenwood Village
- Lakewood - Lakewood
Alabama
- Mobile - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2030-09 |
| Phase | Phase 3 |
What NCT05862272 shows while recruiting
NCT05862272 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 243-participant average among 48 other Endometriosis trials with a reported enrollment target (312% higher).
The record links to 2 conditions, with Endometriosis appearing as the primary indexed condition, and to 1 intervention - of which Relugolix Combination Tablet is the first listed.
NCT05862272 names 20 study sites across 4 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT05862272 about?
NCT05862272 is a clinical study titled "A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis". The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyoma...
What is the current status of trial NCT05862272?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2023-08-14. Estimated completion is 2030-09.
What conditions does trial NCT05862272 study?
This clinical trial studies the following conditions: Endometriosis, Uterine Fibroids.
What interventions are being tested in trial NCT05862272?
The interventions under investigation include: Relugolix Combination Tablet (DRUG).
Who is sponsoring clinical trial NCT05862272?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05862272 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05862272's enrollment target sits among peer trials
1,000 5th of 48 higher than 44 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
RECRUITING · Phase 3
-
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
RECRUITING · Phase 3
-
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
RECRUITING · Phase 3
-
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
ACTIVE NOT RECRUITING · Phase 3
-
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
COMPLETED · Phase 3
-
Medical Treatment of Endometriosis-Associated Pelvic Pain
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI